Glenmark Pharmaceuticals Limited (BOM: 532296)
Market Cap | 459.37B |
Revenue (ttm) | 130.80B |
Net Income (ttm) | -8.75B |
Shares Out | n/a |
EPS (ttm) | -31.02 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | 2.50 (0.15%) |
Ex-Dividend Date | Sep 13, 2024 |
Volume | 3,997 |
Open | 1,615.45 |
Previous Close | 1,622.40 |
Day's Range | 1,615.45 - 1,658.20 |
52-Week Range | 766.65 - 1,830.05 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Feb 7, 2025 |
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/n... [Read more]
Financial Performance
Financial StatementsNews
Pharma Sector Stocks: Torrent Pharma (+0.25%) rises; Glenmark (-2.29%), Aurobindo (-2.02%) decline
The pharma sector showed mixed trends during the session as of 12:15 AM. Torrent Pharma was the only gainer, rising ₹8.45 to ₹3,336.30 (+0.25%). Sun Pharma dipped ₹4.95 to ₹1,800.50 (-0.27%), and Dr. ...
Motilal Oswal’s healthcare sector picks: Sun Pharma, IPCA, Mankind, Ajanta, and Glenmark
Motilal Oswal Financial Services has highlighted key stock recommendations in the healthcare sector, projecting strong growth potential for 2024. The focus includes prominent pharmaceutical companies ...
Glenmark shares surge 4% following positive Phase 1 trial results for ISB 2001
Glenmark Pharmaceuticals saw its stock price rise by 4% after Ichnos Glenmark Innovation (IGI) announced promising Phase 1 clinical trial results for ISB 2001, a trispecific antibody designed to treat...
HSBC cuts target price for Glenmark Pharma shares to Rs 1,600 after Q2 results
HSBC has maintained a 'Hold' rating on Glenmark Pharma while trimming its target price to ₹1,600
Glenmark Pharmaceuticals Q2 FY25 Results: Revenue up 5.6% YoY to ₹3,433.80 crore, profit at ₹354.48 crore versus loss of ₹180.30 crore YoY
Glenmark Pharmaceuticals Ltd. reported a 5.6% year-on-year (YoY) increase in revenue from operations for Q2 FY25, reaching ₹3,433.80 crore compared to ₹3,207.38 crore in Q2 FY24. On a quarter-on-quart...
Glenmark Pharma Q2 results: Check share price ahead of Q2 results
Glenmark Pharmaceuticals shares are currently trading at ₹1,553.60, marking an increase of 0.92% as the company gears up to release its second-quarter earnings. With a total market cap of ₹43,840.75 c...
Stocks to Watch Today: Hindustan Aeronautics, Grasim, Hero MotoCorp, Muthoot Finance, Bharat Forge, Glenmark Pharma to announce Q2 results
Several companies are scheduled to announce their Q2 FY25 earnings today. The last traded price (LTP) from yesterday’s closing is provided below for each company, which could influence market reaction...
Glenmark Pharmaceuticals Q2 FY25 Results: Shares fall over 3% ahead of earnings release
Glenmark Pharmaceuticals Ltd shares were trading 3.25% lower at ₹1,525.75 on the NSE as of 11:37 a.m. on November 13, 2024, as investors anticipated the company’s Q2 FY25 results. Expectations for Gle...
Glenmark Pharma shares recover after 10% drop – Here’s what you need to know
Glenmark Pharmaceuticals shares experienced a sharp 10% plunge earlier today, trading at ₹1,634.7. However, the stock has started to show signs of recovery as of 9:29 AM, trading 1.18% lower at ₹1,614...
Glenmark Life Sciences shares jump 3% following ‘Buy’ upgrade by Kotak
Glenmark Life Sciences witnessed a surge of 3.15% in its share price, reaching ₹967.95 as of 11:38 AM on October 28, 2024. The stock saw positive momentum following Kotak’s double upgrade, which moved...